This includes patients with cTCD (170-199 centimeter per second ) or aTCD (≥ 200 cm/s). TAMMV greater than or equal to (≥) 170 cm/s in the ICA and/or MCA during the Screening Period and confirmed on 2 occasions and without history of primary ischemic or hemorrhagic stroke, transient ischemic attack, or severe central nervous system (CNS) vasculopathy on magnetic resonance angiography (MRA).SCD genotype may be determined from the results of Hb electrophoresis, high-performance liquid chromatography, or similar testing. Documentation of SCD genotype (HbSS, HbSβ0 -thalassemia) based on prior history of laboratory testing.Type of Participant and Disease Characteristics: Patient's parent, legal guardian, or legal representative has provided documented informed consent and patients have provided age-appropriate assentġ2 to 16 years of age (inclusive) at time of screening At the end of the study, if deemed appropriate by you, your child, and the study doctor, your child may be offered the opportunity to participate in a separate study to continue receiving etavopivat. As part of the study, the participants will be asked to visit the clinic frequently. Each dose should be taken with a glass of water. Etavopivat may be taken with or without food. The dose of 400 mg will be taken as 2 tablets by mouth, each containing 200 mg of etavopivat. The participant will take 400 milligrams (mg) of etavopivat once a day for the 52 weeks. The participant will start a 52-week (1 year) treatment period. The study doctor will determine if the TCD result is conditional or abnormal. In another cohort, participants with conditional TCD or participants with abnormal TCD who are receiving a stable dose of hydroxyurea will be included. In one cohort, participants with conditional transcranial doppler (TCD) or participants with abnormal TCD who are not able to receive hydroxyurea will be included. Participants will be divided into two cohorts depending on their transcranial doppler (TCD) ultrasound results and whether or not they receive hydroxyurea (medication that they may already be taking). The study will test a new medicine, etavopivat, for sickle cell disease and see if it is safe and helpful for participants with sickle cell disease who are at an increased risk of stroke. Why Should I Register and Submit Results?.Increase knowledge and confidence to integrate the skills learned in a clinical setting.State the clinical applications and limitations of TCD/TCI examinations.Apply diagnostic criteria for TCD/TCI interpretation.Recognize normal and abnormal intracranial Doppler spectral waveform characteristics.Demonstrate standard scan techniques for performing a TCD and TCI exam.Increase participant’s knowledge to better perform and/or interpret TCD/TCI examinations.This intensive hands-on Introduction to Transcranial Doppler Ultrasound program provides the training needed to immediately begin integrating the newly acquired skills into clinical practice.Īt the completion of the program the participant should be able to: Topics of discussion include neuroanatomy, TCD and TCI examination techniques, evaluation of normal and abnormal TCD/TCI ultrasound characteristics and scan protocols specific to TCD/TCI examinations, which are taught in accordance with AIUM and IAC guidelines. This intro to TCD/TCI course includes lectures, interactive case studies, pathology simulation, and extensive hands on scanning featuring a 3:1 hands-on ratio using live models and an interactive pathology simulator. This course is designed to provide a strong foundation to perform and/or interpret Transcranial Doppler and Transcranial color flow imaging examinations. The Introduction to Transcranial Doppler hands-on course is a live, two-day program taught by leading vascular experts in the field.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |